Editorial: Why JAACAP Published an “Inconclusive” Trial: Optimize, Optimize, Optimize Psychostimulant Treatment

In this issue of the Journal, Blader et al.1 report the results of a double-blind randomized controlled trial (RCT) aimed at assessing the comparative efficacy and tolerability of adjunctive risperidone (RISP), valproex sodium (DVPX) or placebo for aggressive behaviors in children (aged 6-12) with attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD), or conduct disorder (CD), as well as a prior history of psychostimulant treatment. Participants with aggressive symptoms persisting after an open-label optimization of psychostimulant medication entered the 8-week randomized phase.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Tags: Editorial Source Type: research